Recombinant Chimeric antibody to Human CA9. The drug candidate REDECTANE® (INN: 124I-Girentuximab) is based on an antibody and is being developed for the pre-surgical diagnosis of clear cell Renal Cell Cancer. REDECTANE® is the radioactively labelled form of the antibody Girentuximab. Learn more: <a href="https://www.creativebiolabs.net/Anti-Human-CA9-Therapeutic-Antibody-REDECTANE-13805.htm">Iodine (124I) Girentuximab</a>